Capricor Therapeutics (NASDAQ:CAPR) Shares Up 10.6% – Here’s What Happened

Capricor Therapeutics Inc (NASDAQ:CAPR)’s stock price traded up 10.6% on Thursday . The company traded as high as $20.35 and last traded at $20.16. 285,948 shares traded hands during mid-day trading, a decline of 75% from the average session volume of 1,141,996 shares. The stock had previously closed at $18.23.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on CAPR shares. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, October 9th. Oppenheimer reissued an “outperform” rating and set a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Maxim Group raised their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

Capricor Therapeutics Price Performance

The firm has a market capitalization of $894.58 million, a price-to-earnings ratio of -21.18 and a beta of 4.00. The business has a fifty day moving average price of $13.81 and a two-hundred day moving average price of $8.00.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The business had revenue of $3.97 million during the quarter, compared to analyst estimates of $4.51 million. On average, research analysts predict that Capricor Therapeutics Inc will post -1.17 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 12.00% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently modified their holdings of the company. Oppenheimer & Co. Inc. lifted its position in shares of Capricor Therapeutics by 25.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock valued at $1,040,000 after buying an additional 13,762 shares in the last quarter. SG Americas Securities LLC acquired a new position in Capricor Therapeutics during the third quarter worth $133,000. Marshall Wace LLP purchased a new position in Capricor Therapeutics during the second quarter valued at $426,000. Renaissance Technologies LLC grew its position in shares of Capricor Therapeutics by 158.7% in the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the period. Finally, Main Street Financial Solutions LLC increased its stake in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.